Given the increased number of HLA-mismatched haploidentical transplantation with
post-transplant cyclophosphamide performed each year and the high risk of infectious
complications associated with this type of transplant, the investigators suggest that GM-CSF
administration post-infusion of T-replete haploidentical stem cells and post-transplant
cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering
risk of infectious complications.